Datopotamab Deruxtecan Granted Priority Review by FDA for Advanced EGFR-Mutated NSCLC AstraZeneca and Daiichi Sankyo recently announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License…
AbbVie and Simcere Zaiming Announce Partnership to Develop Novel Trispecific Antibody for Multiple Myeloma AbbVie a global leader in oncology and hematology, has joined forces with Simcere Zaiming, a subsidiary…
Eli Lilly and Company has announced its preliminary revenue guidance for 2024 and 2025, showcasing significant growth and momentum in its operations. For 2024, Lilly anticipates full-year worldwide revenue to…
Eli Lilly and Company and Scorpion Therapeutics a private biotechnology company specializing in small molecule precision oncology therapies, have announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor…
Blueprint Medicines Corporation recently unveiled its 2025 corporate outlook and strategic vision for sustained growth, leveraging its established research, development, and commercial expertise. According to Kate Haviland, Chief Executive Officer…
Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership…
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services…
Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth…
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President…
Introduction to Heart Failure and the Need for New Treatments Bayer has announced that it has submitted marketing authorization applications to both the U.S. Food and Drug Administration (FDA) and…
Regenerative Medicine Revolutionary Technologies Behind the Innovation Bio-Techne a renowned global leader in life science tools and reagents, has unveiled an impressive expansion to its R&D Systems AI-engineered designer protein…
Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with…